MDXG : Summary for MiMedx Group, Inc - Yahoo Finance

U.S. Markets closed

MiMedx Group, Inc. (MDXG)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.97+0.02 (+0.19%)
At close: 4:00PM EST

7.93 -0.04 (-0.44%)
After hours: 4:38PM EST

People also watch
OSIRNEOMACKHALOTGTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close7.95
Open7.94
Bid7.82 x 500
Ask8.35 x 100
Day's Range7.83 - 8.06
52 Week Range6.64 - 10.02
Volume1,088,947
Avg. Volume685,460
Market Cap872.29M
Beta0.66
PE Ratio (TTM)44.01
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents5 hours ago

    Edited Transcript of MDXG earnings conference call or presentation 23-Feb-17 3:30pm GMT

    Q4 2016 MiMedx Group Inc Earnings Call

  • PR Newswireyesterday

    MiMedx Announces 2016 Record Results

    MARIETTA, Ga., Feb. 23, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market ...

  • PR Newswire8 days ago

    MiMedx Announces Release Date for 2016 Full Year Results

    MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.